News

Novartis gets FDA ok for Ilaris
Enlarge image

BusinessSwitzerland

Novartis gets FDA ok for Ilaris

13.05.2013 - Swiss Novartis AG has gained authorisation from the FDA to market its IL-2beta blocker Ilaris in childhood arthritis.

The market approval of Novartis’ immune system blocker canakinumab comes only two weeks after the FDA has cleared Roche’s first-in-class IL-6 receptor blocker Actemra (tocilizumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in children aged 2 years and older.

SJIA is a rare, debilitating form of arthritis in children that worsens over time and affects approximately 30 in 100,000 children. The approval of the Novartis once monthly subcutaneously administered human monoclonal antibody was based on two Phase III trials. The first one showed that 84% of patients treated achieved ACR30 versus 10% in the placebo arm at day 15. In an open-label part of the other study, 92 of 128 patients attempted corticosteroid tapering. 57 were able to reduce their use of corticosteroids, and 42 completely discontinued corticosteroids.

Roche had reported that 83% of patients that took its monthly intravenously administered IL 6 receptor antagonist tocilizumab as monotherapy achieved an ACR 30 response at week 16 compared to baseline. Additionally, Actemra-treated children experienced significantly fewer disease flares (26%) compared to placebo-treated patients (48%).

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/novartis-gets-fda-ok-for-ilaris.html

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 One of the biggest pharma mergers of the year has been called off. Abbvie has dropped plans to acquire UK’s Shire following new US tax rules.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

PoliticsEULithuaniaPoland

02.10.2014 New EU commission chief Jean-Claude Juncker is on the defensive after members of Parliament and NGOs criticised his reorganisation of the health technology units.

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN6.46 EUR16.82%
  • CYTOS0.17 CHF13.33%
  • WILEX2.25 EUR7.14%

FLOP

  • 4SC0.87 EUR-1.14%
  • CYTOTOOLS31.45 EUR-0.47%
  • ADDEX3.20 CHF0.00%

TOP

  • BIOFRONTERA2.88 EUR30.9%
  • ADDEX3.20 CHF3.2%
  • HBM84.00 CHF0.6%

FLOP

  • CYTOS0.17 CHF-29.2%
  • PAION2.22 EUR-27.2%
  • 4SC0.87 EUR-25.6%

TOP

  • SANTHERA82.40 CHF2139.1%
  • CO.DON2.58 EUR163.3%
  • PAION2.22 EUR141.3%

FLOP

  • CYTOS0.17 CHF-95.7%
  • 4SC0.87 EUR-50.6%
  • THERAMETRICS0.07 CHF-50.0%

No liability assumed, Date: 19.10.2014